Everest Medicines Limited (01952.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

236.4x

Market Cap

HKD 10.76B

MomentumView details →

1D Return

−1.54%

YTD Return

−13.52%

RSI (14)

52.8

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

236.4x

Market Cap

HKD 10.76B

RSI (14)

52.8

MomentumView details →

1D Return

−1.54%

YTD Return

−13.52%

ProfitabilityView details →

Gross Margin

69.83%

Net Margin

−2.24%

EBITDA Margin

1.61%

ROE (TTM)

−1.03%

ROA (TTM)

−0.64%

Asset Turnover

0.29x

GrowthView details →

Revenue YoY

+182.91%

EPS YoY

+92.18%

FCF YoY

−36.85%

Revenue CAGR 3Y

+410.98%

EPS CAGR 3Y

+72.53%

EBITDA YoY

+114.03%

EarningsView details →

EPS (Actual)

−HKD 0.02

EPS Surprise

97.85%

Beats (12Q)

1/12

Next Q EPS Est

−HKD 5.04

Avg Surprise (4Q)

97.85%

Rev Surprise

−16.55%

Capital & dividendView details →

Debt/Equity

0.38x

Current Ratio

3.77x

Quick Ratio

3.58x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

2.41B

Net Income (TTM)

−53.92M

Op. CF (TTM)

−183.59M

Next earningsApr 1, 2027 →

Latest newsMore news →

On August 20, 2026, Hong Kong-listed biotech stocks surged broadly, with 3D Medicines rising 55%, Everest Medicines rising 50%, CanSino Biologics rising 45%, and other biotech firms gaining sharply.16d ago

Everest Medicines reported interim results for the six months ended June 2026, with revenue of RMB 1.148 billion, up 157.3% year-on-year, and net loss narrowed to RMB 5.944 million from nearly RMB 250 million a year earlier.17d ago

Similar companies

Axsome Therapeutics, Inc.AXSM Krystal Biotech, Inc.KRYS Suzhou Ribo Life Science Co06938.HK 欧林生物688319.SH Apogee Therapeutics, Inc.APGE Bio-Techne CorporationTECH Find similar companies →

Latest newsMore news →

On August 20, 2026, Hong Kong-listed biotech stocks surged broadly, with 3D Medicines rising 55%, Everest Medicines rising 50%, CanSino Biologics rising 45%, and other biotech firms gaining sharply.16d ago Everest Medicines reported interim results for the six months ended June 2026, with revenue of RMB 1.148 billion, up 157.3% year-on-year, and net loss narrowed to RMB 5.944 million from nearly RMB 250 million a year earlier.17d ago